Similar companies
Income Statement (NONE)
| Q1 '25 | QoQ | |
|---|---|---|
| Revenue | 117M | 1882.9% |
| Gross Profit | 116M | 2955% |
| Cost of Revenue | 610,000 | 71% |
| Operating expense | 220M | 4.1% |
| Net Income | -167M | 36.8% |
| EBITDA | -104M | 55.6% |
Balance Sheet (NONE)
| Q1 '25 | QoQ | |
|---|---|---|
| Total Assets | 882M | 4.1% |
| Total Liabilities | 2.52B | 6% |
| Shares Outstanding | 190M | 0.4% |
Cash Flow (NONE)
| Q1 '25 | QoQ | |
|---|---|---|
| Cash from operations | -199M | 2% |
| Cash from financing | 60M | 87.3% |
EPS
Financial Highlights for BridgeBio Pharma in Q1 '25
BridgeBio Pharma reported a revenue of 117M, which is a 1882.9% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 116M, marking a 2955% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 610,000, a -71% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 220M, showing a -4.1% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -167M, showing a 36.8% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -104M, showing a 55.6% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for BridgeBio Pharma with growth in revenue, gross profit, and net income.
